NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$1.36 USD
-0.17 (-11.11%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $1.38 +0.02 (1.47%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NBY 1.36 -0.17(-11.11%)
Will NBY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBY
Brookdale Senior Living (BKD) Reports Q1 Loss, Lags Revenue Estimates
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why
NBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
Other News for NBY
NBY forms 20 Day Moving Average Resistance on October 3
NovaBay (NBY) Files for $200 Million Mixed Securities Shelf
NBY Crossed Above 20 Day Moving Average on October 2
NovaBay files $200M mixed securities shelf
NovaBay files $200M mixed securities shelf